Sleep Well, Wake Up Alert: Eisai and Purdue's Lemborexant Positive in Phase III Trial for Insomnia

Eisai Co., based in Tokyo, and Purdue Pharma, headquartered in Stamford, Conn., announced topline results from their SUNRISE 2 Phase III clinical trial of lemborexant for sleep-wake disorders.

The clinical trial looked at more than 900 patients between the ages of 18 and 88 who had insomnia, characterized by difficulty falling asleep or staying asleep. The trial met the primary and key secondary efficacy objectives based on patient sleep diaries.